A Randomized Phase 3 Trial Of Melphalan-Lenalidomide-Prednisone (MPR) Or Cyclophosphamide-Prednisone-Lenalidomide (CPR) Vs Lenalidomide Plus Dexamethsone (Rd) In Elderly Newly Diagnosed Multiple Myeloma Patients

被引：5
|
作者：
Palumbo, Antonio
Magarotto, Valeria
Bringhen, Sara
Offidani, Massimo
Pietrantuono, Giuseppe
Liberati, Anna Marina
Benevolo, Giulia
Ledda, Antonio
Gilestro, Milena
Galli, Monica
Patriarca, Francesca
Genuardi, Mariella
Giuliani, Nicola
Zambello, Renato
Zdenek, Adam
La Fauci, Alessia
Corradini, Paolo
Falcone, Antonietta Pia
Musolino, Caterina
Rossi, Davide
Caraffa, Patrizia
Musto, Pellegrino
Cavallo, Federica
Hajek, Roman
Boccadoro, Mario
机构：
来源：
BLOOD | 2013年 / 122卷 / 21期
关键词：
D O I：
10.1182/blood.V122.21.536.536
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
536
引用
收藏
页数：2
相关论文
共 50 条
  • [41] Melphalan, prednisone, lenalidomide versus melphalan (200 mg/m2) and autologous transplantation in newly diagnosed myeloma patients: a phase III trial
    Palumbo, A.
    Cavallo, F.
    Nagler, A.
    Gay, F.
    Catalano, L.
    Baraldi, A.
    Galli, M.
    Pescosta, N.
    Cangialosi, C.
    Cascavilla, N.
    Benevolo, G.
    Ria, R.
    Rossi, D.
    Olivero, B.
    Guglielmelli, T.
    Gamberi, B.
    Redoglia, V.
    Di Toritto, T. Caravita
    Di Raimondo, F.
    Boccadoro, M.
    BONE MARROW TRANSPLANTATION, 2011, 46 : S38 - S38
  • [42] Comparison of Sequential Vs Alternating Administration of Bortezomib, Melphalan, Prednisone (VMP) and Lenalidomide Plus Dexamethasone (Rd) in Elderly Pts with Newly Diagnosed Multiple Myeloma (MM) Patients: GEM2010MAS65 Trial
    Mateos, Maria-Victoria
    Martinez-Lopez, Joaquin
    Hernandez, Miguel-T
    Martinez, Rafael
    Rosinol, Laura
    Ocio, Enrique M.
    Asuncion Echeveste, Maria
    Perez de Oteyza, Jaime
    Oriol, Albert
    Bargay, Joan
    Gironella, Mercedes
    Martin, Jesus
    Cabrera, Carmen
    De La Rubia, Javier
    Gutierrez, Norma C.
    Martin, Maria-Luisa
    Paiva, Bruno
    Angeles Montalban, Maria
    Blade, Joan
    Jose Lahuerta, Juan
    San Miguel, Jesus F.
    BLOOD, 2014, 124 (21)
  • [43] Phase I-II Trial of Oral Cyclophosphamide, Prednisone and Lenalidomide (Revlimid®) (CPR) for the Treatment of Patients with Relapsed and Refractory Multiple Myeloma
    Reece, Donna E.
    Masih-Khan, Esther
    Khan, Arooj
    Anglin, Peter
    Chen, Christine
    Kukreti, Vishal
    Mikhael, Joseph R.
    Truidel, Suzanne
    BLOOD, 2008, 112 (11) : 607 - 607
  • [44] Phase I-II Trial of Oral Cyclophosphamide, Prednisone and Lenalidomide (Revlimid®) (CPR) for the Treatment of Patients with Relapsed and Refractory Multiple Myeloma
    Reece, Donna E.
    Masih-Khan, Esther
    Khan, Arooj
    Dean, Saima
    Fung, Sharon
    Anglin, Peter
    Chen, Christine
    Kukreti, Vishal
    Mikhael, Joseph R.
    Trudel, Suzanne
    BLOOD, 2010, 116 (21) : 1260 - 1260
  • [45] Phase I-II Trial of Oral Cyclophosphamide, Prednisone and Lenalidomide (Revlimid®) (CPR) for the Treatment of Patients with Relapsed and Refractory Multiple Myeloma
    Reece, Donna E.
    Masih-Khan, Esther
    Khan, Arooj
    Dean, Saima
    Anglin, Peter
    Chen, Christine
    Kukreti, Vishal
    Mikhael, Joseph R.
    Trudel, Suzanne
    BLOOD, 2009, 114 (22) : 744 - 744
  • [46] Melphalan, Prednisone and Lenalidomide Followed by Lenalidomide Maintenance Displays Treatment Characteristics Favourable to Global Quality of Life in Newly Diagnosed Multiple Myeloma (NDMM) Patients ≥ 65 Years
    Dimopoulos, Meletios Athanasios
    Palumbo, Antonio
    Hajek, Roman
    Kropff, Martin
    Petrucci, Maria Teresa
    Lewis, Philip
    Millar, Stefanie
    Zhang, Jingshan
    Mei, Jay
    Delforge, Michel
    BLOOD, 2011, 118 (21) : 1706 - 1707
  • [47] Lenalidomide and low-dose dexamethasone (Rd) versus bortezomib, melphalan, prednisone (VMP) in elderly newly diagnosed multiple myeloma patients: A comparison of two prospective trials
    Gentile, Massimo
    Magarotto, Valeria
    Offidani, Massimo
    Musto, Pellegrino
    Bringhen, Sara
    Petrucci, Maria Teresa
    Gay, Francesca
    Larocca, Alessandra
    Uccello, Giuseppina
    Petrungaro, Annamaria
    Vigna, Ernesto
    Greco, Rosa
    Recchia, Anna Grazia
    Tripepi, Giovanni
    Ria, Roberto
    Di Raimondo, Francesco
    Palumbo, Antonio
    Morabito, Fortunato
    AMERICAN JOURNAL OF HEMATOLOGY, 2017, 92 (03) : 244 - 250
  • [48] COST-EFFECTIVENESS IN NEWLY DIAGNOSED MULTIPLE MYELOMA (NDMM): LENALIDOMIDE PLUS LOW-DOSE DEXAMETHASONE (RD) VERSUS BORTEZOMIB PLUS MELPHALAN AND PREDNISONE (VMP)
    Cavenagh, J. D.
    Belch, A. R.
    Hulin, C.
    Basu, S.
    White, D.
    Ervin-Haynes, A.
    Marek, J.
    Pelligra, C. G.
    Guo, S.
    Binder, G.
    Monzini, M. S.
    Facon, T.
    HAEMATOLOGICA, 2014, 99 : 379 - 379
  • [49] Oral Melphalan, Prednisone, and Lenalidomide for Newly Diagnosed Multiple Myeloma Patients: Kinetics of Neutropenia/Thrombocytopenia and Time to Event Results.
    Palumbo, Antonio
    Falco, Patrizia
    Gay, Francesca
    Corradini, Paolo
    Crippa, Claudia
    Di Raimondo, Francesco
    Falcone, Antonietta
    Giuliani, Nicola
    Musto, Pellegrino
    Morabito, Fortunato
    Canepa, Letizia
    Gozzetti, Alessandro
    Caltagirone, Simona
    Zeldis, Jerome B.
    Knight, Robert D.
    Boccadoro, Mario
    Petrucci, Maria Teresa
    BLOOD, 2008, 112 (11) : 955 - 955
  • [50] Phase II Study of Melphalan, Prednisone and Lenalidomide Combination for Newly Diagnosed Multiple Myeloma Patients Who Are Not Candidates for Stem Cell Transplantation.
    Roy, Vivek
    Stewart, A. Keith
    Bergsagel, P. Leif
    Dispenzieri, Angela
    Laumann, Kristina
    Allred, Jake
    Lacy, Martha Q.
    Fonseca, Rafael
    Reeder, Craig B.
    Kumar, Shaji
    Rivera, Candido E.
    Gertz, Morie A.
    Greipp, Philip R.
    Buadi, Francis K.
    Hayman, Suzanne R.
    Rajkumar, S. Vincent
    BLOOD, 2008, 112 (11) : 955 - 955
12345